We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics' Plasma Momentum Solid, Margins Gain Traction
Read MoreHide Full Article
On Jun 15, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from continued momentum in new business generation and expanding geographies. The stock carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the last three months. The stock has rallied 24.8% compared with the industry’s 5.6% rise.
Haemonetics exited fourth-quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. Consistent momentum in new business formation along with widening global footprint has also helped the company deliver strong results. Moreover, the gross and operating margin growth buoys optimism among investors about the stock.
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. For solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Further, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems including the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect any quick recovery in the Blood Center’s outcome, which further adds to our concerns.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Abiomed, Inc. , Stryker Corporation (SYK - Free Report) and Intuitive Surgical Inc. (ISRG - Free Report) .
Abiomed has a projected long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1 (Strong Buy).
Stryker has an estimated long-term earnings growth rate of 9.7%. The stock holds a Zacks Rank of 2.
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Haemonetics' Plasma Momentum Solid, Margins Gain Traction
On Jun 15, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from continued momentum in new business generation and expanding geographies. The stock carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the last three months. The stock has rallied 24.8% compared with the industry’s 5.6% rise.
Haemonetics exited fourth-quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. Consistent momentum in new business formation along with widening global footprint has also helped the company deliver strong results. Moreover, the gross and operating margin growth buoys optimism among investors about the stock.
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. For solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Further, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems including the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect any quick recovery in the Blood Center’s outcome, which further adds to our concerns.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Abiomed, Inc. , Stryker Corporation (SYK - Free Report) and Intuitive Surgical Inc. (ISRG - Free Report) .
Abiomed has a projected long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1 (Strong Buy).
Stryker has an estimated long-term earnings growth rate of 9.7%. The stock holds a Zacks Rank of 2.
Intuitive Surgical has an expected long-term earnings growth rate of 12.1% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>